The Rise, Fall and Future of Novavax

It could have been a fairytale story. A small American vaccine maker rises to save the day during the pandemic of a century - and ascends to the top of its class.

Instead, on Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024.